Emerging Strategies Targeting the PI3K/AKT/mTOR Pathway in HR+/HER2– Advanced Breast Cancer

Drugs · Published 2026-07-28 · DOI 10.1007/s40265-026-02347-5

Free full text

Authors (8)

Lan Lei, Madison Canning, Elizabeth Sakach, Almeera Lateef, Larisa Kamga, Minaam Abid, Kevin Kalinsky, Shipra Gandhi

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Lei, L., Canning, M., Sakach, E., et al. (2026). Emerging Strategies Targeting the PI3K/AKT/mTOR Pathway in HR+/HER2– Advanced Breast Cancer. Drugs. https://doi.org/10.1007/s40265-026-02347-5

Related articles

• Sibeprenlimab: First Approval · Drugs · 2026 · Same journal
• The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir · Drugs · 2026 · Same journal
• Ecnoglutide: First Approvals · Drugs · 2026 · Same journal
• Recaticimab: The First Fc-Engineered PCSK9 Monoclonal Antibody for More Long-Lasting Effect in Lipid Lowering · Drugs · 2026 · Same journal
• Etripamil: First Approval · Drugs · 2026 · Same journal
• Long-Acting Lipoglycopeptide Treatment of Invasive Gram-Positive Infections · Drugs · 2026 · Same journal
• Emerging Cardiorenal Protective Therapies in Lupus Nephritis · Drugs · 2026 · Same journal
• Reframing the High-density Lipoprotein (HDL) Hypothesis in Light of Clinical Trials of Cholesterol Ester Transfer Protein (CETP) Inhibitors · Drugs · 2026 · Same journal
• Treating Pancreatic Ductal Adenocarcinoma: The Targeted Revolution is Here · Drugs · 2026 · Same journal
• The Role of β-Blockers in the Evolving Treatment Landscape of Resistant Hypertension · Drugs · 2026 · Same journal